The structure-guided discovery of osimertinib: the first U.S. FDA approved mutant selective inhibitor of EGFR T790M†
Abstract
A graphical abstract is available for this content
Please wait while we load your content...
Article information
- Article type
- Editorial
- Submitted
- 21 Mar 2017
- Accepted
- 21 Mar 2017
- First published
- 10 May 2017
Med. Chem. Commun., 2017,8, 820-822
Permissions
The structure-guided discovery of osimertinib: the first U.S. FDA approved mutant selective inhibitor of EGFR T790M
S. Butterworth, D. A. E. Cross, M. R. V. Finlay, R. A. Ward and M. J. Waring, Med. Chem. Commun., 2017, 8, 820 DOI: 10.1039/C7MD90012K
To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.
If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.
If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.
Read more about how to correctly acknowledge RSC content.